Compare Regeneron Pharmaceuticals Inc (REGN) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wendys Co — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Wendys Co trades at $7.53 (market cap $1.45B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 57.5× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| REGN | WEN | |
|---|---|---|
Market Cap | $83.43B | $1.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $9.89 |
52-Week Low | $555.51 | $6.17 |
Enterprise Value | $78.14B | $5.18B |
Dividend Yield | 0.46% | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Wendy's stock (WEN) trades at $7.61, down 5.23% over 24 hours, reflecting recent volatility after takeover speculation faded. The stock shows a bearish technical trend with key support at $7 and resistance at $8. Fundamentally, the company has beaten EPS estimates for three consecutive quarters but faces declining net income margins, from 7.58% in 2025 to 5.72% projected for 2026. Recent news highlights CEO Bob Wright's turnaround efforts, including a new marketing chief appointment to address quality and traffic declines.
The outlook is mixed: valuation ratios like P/E of 11.54 and P/S of 0.66 appear attractive relative to peers, but execution risks persist amid competitive pressures. Analyst consensus is cautious with 64.71% hold ratings, though the $8.13 price target implies modest upside. Key risks include sustained traffic declines and high debt levels, with debt-to-asset ratio rising to 55.68% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
